重组人脑利钠肽治疗重症心肌炎合并心力衰竭患者临床观察  

Clinical study of recombinant human brain natriuretic peptide treating severe myocarditis with heart failure

作　　者：邵元霞[1] SHAO Yuanxia(Jining First People＇ s Hospital ＆the Affiliated Hospital of Jining Medical University,Jining 272000, Chin)

机构地区：[1]济宁医学院附属济宁市第一人民医院,济宁272000

出　　处：《济宁医学院学报》2016年第6期399-401,共3页Journal of Jining Medical University

摘　　要：目的探讨重组人脑利钠肽(rh BNP)在重症心肌炎合并心力衰竭患者中应用的临床疗效。方法选取2012年7月至2016年6月在我院住院治疗的急性心肌炎合并心力衰竭患者108例,随机分为观察组(50例)和对照组(58例)。两组均给予常规抗心力衰竭治疗,观察组在常规治疗的基础上静脉泵入rh BNP(先以负荷剂量1.5μg/kg静推,再予维持剂量0.0075μg/kg/min持续泵入)。治疗72h后观察两组患者用药前后血清N末端脑钠肽前体(NT-pro BNP)水平、超声心动图评价左室射血分数(LVEF),并重新评估患者心功能(NYHA分级)及Super-Score评分。结果治疗后两组NT-pro BNP水平均下降,观察组更明显(P<0.05),两组LVEF值、心功能均提高,观察组更明显(P<0.05)。结论 rh-BNP治疗重症心肌炎合并心力衰竭患者疗效显著,可明显改善患者的心力衰竭症状。Objective To investigate the clinical effects of recombinant human brain natriuretic peptide （ rh-BNP） in the treatment of severe myocarditis with heart failure.Methods A total of 108 patients with se-vere myocarditis heart failure at our hospital from July 2012 to June 2016 were randomly divided into rh-BNP treatment group （50 cases） and conventional treatment group （58 cases）.Both groups were treated with conventional drugs against heart failure.Besides routine therapy,the rh-BNP group received rhBNP （1.5μg/kg bolus intravenous injection followed by 0.0075μg/kg/min continuous infusion）.The plasma NT-prdBNP and LV EF value were evaluated by Ultrasonic echocardiography.NYHA heart function classification and SU-PER SCORE of two groups were reappraised before and after treatment were observed.Results Compared with before treatment in 72 hours,both group were significantly lower in NT-proBNP and higher in LVEF val-ue and heart function.Treatment group were more obvious than control group （ P〈0.05）.Conclusion Rh-BNP,being capable of ameliorating heart failure symptoms of patients evidently,has significant therapeutic effects in the treatment of heart failure in patients with severe myocarditis.

关 键 词：重组人脑利钠肽 重症心肌炎 心力衰竭 左室射血分数 Super-Score评分 

分 类 号：R541[医药卫生—心血管疾病]